Sara Khan, DO, on the Gender Gap in Receiving NIH Grants for Hematology Research
2023 ASH
Sara Khan, DO, of the University of South Florida Morsani College of Medicine and HCA Healthcare, discusses her findings showing that women received only 33% of grants from the National Institutes of Health from 2012 to 2022 in nonmalignant hematologic research. Although some agencies have made strides in this area, others continue to have a significant gap. Identifying these areas of gender disparity will enable targeted efforts to bridge this gap and advance gender equality (Abstract 5113).
The ASCO Post Staff
Andrew Srisuwananukorn, MD, of The Ohio State University Comprehensive Cancer Center, discusses a novel artificial intelligence model that can distinguish between prefibrotic primary myelofibrosis and essential thrombocythemia. This proposed model may assist clinicians in identifying patients who may benefit from disease-specific therapies or enrollment in clinical trials (Abstract 901).
The ASCO Post Staff
Jeffrey E. Rubnitz, MD, PhD, of St. Jude Children’s Research Hospital, discusses study findings suggesting that pharmacogenomic differences between Black and White patients should be considered when tailoring induction regimens to improve outcomes of all patients and bridge the racial disparity gap in acute myeloid leukemia treatment (Abstract 386).
The ASCO Post Staff
Danai Dima, MD, of the Taussig Cancer Institute, Cleveland Clinic, discusses teclistamab-cqyv, a B-cell maturation antigen approved in October 2022 for patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. Dr. Dima and her team evaluated the real-world safety and efficacy of this agent and found encouraging evidence of efficacy in a real-world setting (Abstract 91).
The ASCO Post Staff
Mikkael A. Sekeres, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, reviews key abstracts from ASH 2023 on treatment of myelofibrosis, chronic lymphocytic leukemia, large B-cell lymphoma, and acute myeloid leukemia (Abstracts 620, 631, 781, 425).
The ASCO Post Staff
Ibrahim Aldoss, MD, of City of Hope National Medical Center, discusses phase II safety and efficacy results from the Augment-101 study. This trial showed that patients with heavily pretreated, relapsed or refractory KMT2-rearranged acute leukemia benefited from monotherapy with the menin-KMT2A inhibitor revumenib, with high overall response rates and undetectable measurable residual disease (Abstract LBA-5).
